GB Sciences (GBLX) 10-Q 27 Nov 24 2025 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Jun. 30, 2024	Nov. 27, 2024
Document Information [Line Items]
Entity Central Index Key	0001165320
Entity Registrant Name	GB SCIENCES INC
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2025
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	000-55462
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	59-3733133
Entity Address, Address Line One	9205 W. Russell Road, Suite 240
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89148
City Area Code	866
Local Phone Number	721-0297
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		407,071,028

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2024	Mar. 31, 2024
Cash and cash equivalents	$ 0	$ 11,991
Prepaid expenses and other current assets	91,451	91,451
TOTAL CURRENT ASSETS	91,451	103,442
CURRENT LIABILITIES:
Accrued interest	487,974	457,093
Accrued liabilities	67,500	0
Notes and convertible notes payable	1,437,307	1,437,307
Income tax payable	1,060,825	1,060,825
TOTAL CURRENT LIABILITIES	5,358,584	5,095,557
Convertible notes payable, non-current	322,000	322,000
TOTAL LIABILITIES	5,680,584	5,417,557
Commitments and contingencies (Note 5)
STOCKHOLDERS' DEFICIT:
Common Stock, $0.0001 par value, 950,000,000 shares authorized, 407,071,028 and 406,071,028 outstanding at June 30, 2024 and March 31, 2024, respectively	40,821	40,721
Additional paid-in capital	104,722,056	104,712,156
Accumulated deficit	(110,352,010)	(110,066,992)
TOTAL STOCKHOLDERS' DEFICIT	(5,589,133)	(5,314,115)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	91,451	103,442
Nonrelated Party [Member]
CURRENT LIABILITIES:
Accounts payable	2,170,029	2,012,896
Related Party [Member]
CURRENT LIABILITIES:
Accounts payable	$ 134,949	$ 127,436

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2024	Mar. 31, 2024
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	950,000,000	950,000,000
Common stock, shares issued (in shares)	407,071,028	406,071,028
Common stock, shares outstanding (in shares)	407,071,028	406,071,028

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) $ / shares in Thousands	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Sales revenue	$ 0	$ 0
Cost of goods sold	0	0
Gross profit	0	0
General and administrative expenses	254,137	265,122
LOSS FROM OPERATIONS	(254,137)	(265,122)
OTHER (EXPENSE) INCOME
Interest expense	(30,881)	(40,804)
Other income (Note 7)	0	75,000
Loss on impairment of capitalized patent and trademark costs	0	(42,195)
Total other expense	(30,881)	(7,999)
LOSS BEFORE INCOME TAXES	(285,018)	(273,121)
Income tax expense	0	0
NET LOSS	(285,018)	(273,121)
Deemed dividend	(3,462)	0
Net loss attributable to common shareholders	$ (288,480)	$ (273,121)
Net loss per common share – basic and diluted (in dollars per share)	$ 0	$ 0
Weighted average common shares outstanding - basic and diluted (in shares)	406,565,533	381,872,561

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2024
OPERATING ACTIVITIES:
Net loss	$ (285,018)	$ (273,121)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	0	624
Amortization of debt discount and beneficial conversion feature	0	15,075
Loss on impairment of capitalized patent and trademark costs	0	42,195
Changes in operating assets and liabilities:
Accounts payable	164,646	84,197
Accrued liabilities	67,500	0
Accrued interest	30,881	25,729
Net cash used in operating activities	(21,991)	(105,301)
FINANCING ACTIVITIES:
Gross proceeds from warrant exercises	10,000	0
Proceeds from issuing convertible note	0	25,000
Net cash provided by financing activities	10,000	25,000
Net change in cash and cash equivalents	(11,991)	(80,301)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	11,991	109,912	$ 109,912
CASH AND CASH EQUIVALENTS AT END OF PERIOD	0	29,611	$ 11,991
Supplemental Cash Flow Information [Abstract]
Cash paid for interest	0	0
Cash paid for income tax	0	0
Non-cash investing and financing transactions:
Deemed dividend	$ 3,462	$ 0

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Mar. 31, 2023	381,872,561
Balance at Mar. 31, 2023	$ 38,187	$ 104,259,745	$ (108,705,315)	$ (4,407,383)
Stock issued for cash, net of offering costs (in shares)	0
Stock issued for cash, net of offering costs	$ 0	0	0	0
Share based compensation expense	0	0	0	0
Net income (loss)	$ 0	0	(273,121)	(273,121)
Deemed dividend				0
Balance (in shares) at Jun. 30, 2023	381,872,561
Balance at Jun. 30, 2023	$ 38,187	104,259,745	(108,978,436)	(4,680,504)
Balance (in shares) at Mar. 31, 2024	406,071,028
Balance at Mar. 31, 2024	$ 40,721	104,712,156	(110,066,992)	(5,314,115)
Net income (loss)	$ 0	0	(285,018)	(285,018)
Exercise of warrants (in shares)	1,000,000
Exercise of warrants	$ 100	9,900	0	10,000
Warrant repricing	0	(3,462)	0	(3,462)
Deemed dividend	$ 0	3,462	0	3,462
Balance (in shares) at Jun. 30, 2024	407,071,028
Balance at Jun. 30, 2024	$ 40,821	$ 104,722,056	$ (110,352,010)	$ (5,589,133)

Note 1 - Background and Signifi

Note 1 - Background and Significant Accounting Policies	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 1 Background and Significant Accounting Policies Business GB Sciences, Inc. (“the Company”, “GB Sciences”, “we”, “us”, or “our”) is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its wholly owned Canadian subsidiary, GbS Global Biopharma, Inc. (“GBSGB”). Through GBSGB, the Company is engaged in the research and development of plant-inspired medicines, with virtual operations in North America and Europe. GBSGB’s assets include a portfolio of intellectual property containing both proprietary plant-inspired formulations and our AI-enabled drug discovery platform, as well as critical research contracts and key supplier arrangements. The Company’s intellectual property portfolio, which is held by GBSGB, contains eight twelve two fifteen forty-one The Company was incorporated in the State of Delaware on April 4, 2001, March 28, 2008, On April 4, 2014, December 12, 2016, Effective April 8, 2018, August 15, 2019, March 09, 2023, Recent Developments Intellectual Property Portfolio In the past year, GBLX/GBSGB’s foreign patents for plant-based treatments of serious disorders were allowed in different countries, expanding our patent protections as follows. On February 3, 2023, first $8.8 2026, December 1, 2022, December 15, 2022, February 20, 2023, March 9, 2023, No. 16/878,295. April 25, 2023, In 2021, July 2021 October 2021. July 2021. September 2021, six In 2020, three No. 10,653,640 May 19, 2020 $52 first first one 60 The issuance of the Company’s second third TRPV1” $560 $650 20.4% The Company's third no two no The Company’s fourth March 1, 2022 TRPV1 Licensing Agreement On September 26, 2024, GB Sciences will contribute the following to the intellectual property license: 1. Intellectual property protecting proprietary formulations for the treatment of neurological disorders, including, but not 2. An exclusive license to develop, manufacture, and sell these treatments for neurological disorders in Brazil. 3. An exclusive license for EndoPure to develop, manufacture, and sell specifically-approved treatments in South America to be granted after EndoPure has successfully obtained regulatory approvals to market the products in Brazil. In consideration of this intellectual property license, EndoPure will pay the following: 1. A royalty equal to 5% of gross sales of any product developed and manufactured pursuant to the IP license agreement in the agreed upon territories. 2. An annual pre-paid minimum royalty of $50,000 per product for three one 3. An upfront payment of approximately $125,000 USD disbursed directly to Catalent Pharmaceuticals, Inc. (“Catalent”), which is related to the development and contract manufacturing of these licensed products within Catalent’s proprietary Zydis® orally dissolving tablet (“ODT”) dosage format. 4. A consulting fee of $5,000 per month as compensation for the assistance of Dr. Andrea Small-Howard in the planning and execution of clinical development for these products. Basis of Presentation The accompanying unaudited interim consolidated financial statements of GB Sciences, Inc. have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 8 X. not not may March 31, 2025. June 30, 2024 not 10 March 31, 2024. Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation. All subsidiaries were wholly owned by the Company for the periods presented. Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, collectability of notes receivable, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation and other loss contingencies. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may Fair Value of Financial Instruments The Company adopted ASC 820, 820 820 three three - Level 1 - Level 2 - Level 3 The carrying value of cash, accounts receivable, accounts payable and accrued expenses are estimated by management to approximate fair value, primarily due to the short-term nature of the instruments. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three no June 30, 2024 2023. Indefinite and Definite-Lived Intangible Assets Capitalized costs related to our indefinite-lived intangible assets consisted primarily of the value of our patents pending and includes the costs paid to draft and file patent applications. Upon issuance of the patents, the indefinite-lived intangible assets will have finite lives. Intangible assets also historically included the acquisition cost of a cannabis production license with an indefinite life. We historically amortized our finite-lived intangible assets, which consisted of granted patents, over their estimated useful lives using the straight-line method, and we periodically evaluate the remaining useful lives of our finite-lived intangible assets to determine whether events or circumstances warrant a revision to the remaining period of amortization. We review all of our intangible assets for impairment indicators throughout the year. Impairment testing for indefinite-lived intangible assets is performed at least annually and we perform testing for definite-lived intangible assets whenever impairment indicators are present. If we determine that the fair value is less than the carrying value of these assets during testing, we record impairment losses equal to the difference between the carrying value of the asset and the fair market value of the asset. As of March 31, 2024, March 31, 2023 350 30 35. At June 30, 2024, eight twelve two fifteen forty-one January 2038 May 2039. June 30, 2024 2023, June 30, 2024 2023. There were 10 United States patent applications that are pending as of June 30, 2023, June 30, 2023. June 30, 2024 2023. Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company’s only material revenue source is part of discontinued operations and derives from sales of cannabis and cannabis products, distinct physical goods. Under ASC 606, may may one 606 not Equity-Based Compensation The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 718 no may may may Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company operated in the State-licensed cannabis industry until the December 31, 2021 280E “280E” 280E, no not may not 280E. Loss per Share The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the year. The Company had 167,396,125 and 162,611,301 potentially dilutive common shares including convertible debt, stock options and warrants at June 30, 2024 2023, not Recent Accounting Pronouncements Standards Not All other newly issued accounting pronouncements have been deemed either immaterial or not

Note 2 - Going Concern

Note 2 - Going Concern	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	Note 2 Going Concern The Company’s unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of $110,352,010 at June 30, 2024. June 30, 2024, June 30, 2023. three June 30, 2024, three June 30, 2023. Management has been able, thus far, to finance the losses through debt financing, a public offering, private placements and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no In view of these conditions, the Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Accordingly, there is substantial doubt about the Company to continue as a going concern for a period of twelve not may

Note 3 - Notes and Convertible

Note 3 - Notes and Convertible Notes Payable and Line of Credit	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 3 Notes and Convertible Notes Payable and Line of Credit Summary of Notes Payable and Convertible Notes Payable As of June 30, 2024 2023 As of June 30, 2024 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (as amended) $ 55,307 $ - $ 55,307 6% Convertible promissory notes payable 560,000 - 560,000 6% Convertible notes payable due January 18, 2022 325,000 - 325,000 6% Convertible note payable due July 1, 2022 (Note 6) 50,000 - 50,000 6% Convertible promissory notes payable due September 30, 2023 197,000 - 197,000 6% Convertible note payable due December 31, 2023 250,000 - 250,000 Total short-term notes and convertible notes payable $ 1,437,307 $ 1,437,307 6% Convertible note payable due June 29, 2026 25,000 - 25,000 6% Convertible note payable due July 10, 2026 50,000 - 50,000 6% Convertible notes payable due January-February 2027 247,000 - 247,000 Total notes and convertible notes payable $ 1,759,307 $ - $ 1,759,307 As of March 31, 2024 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (as amended) $ 55,307 $ - $ 55,307 6% Convertible promissory notes payable 560,000 - 560,000 6% Convertible notes payable due January 18, 2022 325,000 - 325,000 6% Convertible note payable due July 1, 2022 (Note 6) 50,000 - 50,000 6% Convertible promissory notes payable due September 30, 2023 197,000 - 197,000 6% Convertible note payable due December 31, 2023 250,000 - 250,000 Total short-term notes and convertible notes payable $ 1,437,307 $ 1,437,307 6% Convertible note payable due June 29, 2026 25,000 - 25,000 6% Convertible note payable due July 10, 2026 50,000 - 50,000 6% Convertible notes payable due January-February 2027 247,000 - 247,000 Total notes and convertible notes payable $ 1,759,307 $ - $ 1,759,307 0% October 23, 2017 On October 23, 2017, one three January 1, 2018. On August 10, 2020, December 31, 2021 December 14, 2021. On March 4, 2022, March 4, 2022. At June 30, 2024, June 30, 2024. March 2017 July 2017 In March 2017, third three March 2017 May 2017, three three In July 2017, third three July 2017 December 2017, three three All notes from the March July 2017 March 31, 2022, $197,000 three September 30, 2023. 10% June 30, 2024 2023, June 30, 2024. Three convertible notes totaling $1,060,000 were held by the same investor and in default. On January 20, 2022, one not June 30, 2024 2023, no June 30, 2024. December 2020 $700,000 6% On December 18, 2020, 19 three January 31, 2021 July 1, 2022, December 2023. March 31, 2022, $.03 November 13, 2023 $.03 $.01 December 31, 2023. not $.03 $.01 no During the year ended March 31, 2024, June 30, 2026 July 10, 2026, no June 30, 2024 2023, December 2020 6% June 30, 2024. January 2024 $247,000 6% From January 22, 2024 February 7, 2024, 13 three 90 no June 30, 2024 2023, June 30, 2024.

Note 4 - Capital Transactions

Note 4 - Capital Transactions	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Equity [Text Block]	Note 4 Capital Transactions Quarter ended June 30, 2024 Warrants During the quarter ended June 30, 2024, May 16, 2024 470, During the quarter ended June 30, 2024, During the quarter ended June 30, 2024, Year ended March 31, 2024 Warrants During the year ended March 31, 2024, September 1, 2023. 470, During the year ended March 31, 2024, During the year ended March 31, 2024, During the year ended March 31, 2024, Warrants Outstanding Presented below is a summary of the Company’s warrant activity, exclusive of warrants held by employees, for the periods ended June 30, 2024 March 31, 2024: Warrants Outstanding Number of Shares Exercise Price Warrants issued (including reinstated) 23,006,492 $0.01 Warrants exercised (25,348,467 ) $0.01 Warrants expired/cancelled (38,337,538 ) $0.01 - $0.60 Outstanding at March 31, 2024 82,079,164 Warrants issued - $0.00 Warrants exercised (1,000,000 ) $0.01 Warrants expired/cancelled (6,293,335 ) $0.10 - $0.25 Outstanding at June 30, 2024 74,785,829 Employee Option Grants A summary of employee option activity, including warrants issued to employees, as of June 30, 2024 2023, Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Employee options Options Price $ Life (years) Value ($) Exercisable at March 31, 2023 17,733,334 $ 0.11 Granted 15,000,000 $ 0.01 Exercised - $ - Expired (2,700,000 ) $ 0.11 Forfeited (1,150,000 ) $ 0.05 Outstanding at March 31, 2024 28,883,334 $ 0.06 $ 7.06 $ - Fully vested and expected to vest at March 31, 2024 28,883,334 $ 0.06 Exercisable at March 31, 2024 28,883,334 $ 0.06 Granted - $ - Exercised - $ - Expired - $ - Forfeited - $ - Outstanding at June 30, 2024 28,883,334 $ 0.06 $ 7.06 $ - Fully vested and expected to vest at June 30, 2024 28,883,334 $ 0.06 Exercisable at June 30, 2024 28,883,334 $ 0.06 The table below sets forth nonemployee option activity for the quarters ended June 30, 2024 2023 Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Nonemployee options Options Price $ Life (years) Value ($) Exercisable at March 31, 2023 6,483,000 $ 0.13 Granted 8,000,000 $ 0.01 Exercised - Forfeited - Outstanding at March 31, 2024 14,483,000 $ 0.06 7.58 -Fully vested and expected to vest at March 31, 2024 14,483,000 $ 0.06 Exercisable at March 31, 2024 14,483,000 $ 0.06 Granted - Exercised - Forfeited - Outstanding at June 30, 2024 14,483,000 $ 0.06 7.58 -Fully vested and expected to vest at June 30, 2024 14,483,000 $ 0.06 Exercisable at June 30, 2024 14,483,000 $ 0.06 Restricted stock awards No restricted stock awards were granted during the quarters ended June 30, 2024 2023.

Note 5 - Commitments and Contin

Note 5 - Commitments and Contingencies	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 5 Commitments and Contingencies On April 11, 2022, May 2020. may From time to time, the Company may not The Company is currently involved in projects for which the Company has contracts with vendors and for which the Company has been invoiced approximately $235,000. Work on these projects will not 2025, not

Note 6 - Related Party Transact

Note 6 - Related Party Transactions	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 6 Related Party Transactions As of June 30, 2024, June 30, 2024 As of June 30, 2024, As of June 30, 2024 March 31, 2024,

Note 7 - Note Receivable from S

Note 7 - Note Receivable from Sale of Membership Interests in Nevada Subsidiaries	3 Months Ended
	Jun. 30, 2024
Nevada Subsidiaries [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 7 Note Receivable from Sale of Membership Interests in Nevada Subsidiaries On March 24, 2020, On August 10, 2020, 483 October 23, 2017 ( 5 The closing of the Teco and Nopah sales was contingent upon the successful transfer of the Nevada cultivation and production licenses. On December 14, 2021, December 31, 2021. As consideration for the membership interests, the Company received cash payments of $1,648,772 (including $400,000 in advance payments received during the nine December 31, 2021), The $3,025,000 note receivable from the sale of the Teco Subsidiaries was initially payable as quarterly, interest only payments of $60,500 for the first March 31, 2023, December 31, 2024. The note contains a provision that allows payments of principal and interest due prior to the maturity date to be postponed to the next quarterly payment date if cash flow from the operations of the facility is insufficient to cover the amount of the payment. Several days prior to the first April 1, 2022, April 1, 2022 July 1, 2022 December 31, 2022 On March 27, 2023, Further in connection with the execution of the March 27, 2023 September 30, 2023, September 30, 2023, September 30, 2023, September 30, 2023

Note 8 - Subsequent Events

Note 8 - Subsequent Events	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	Note 8 Subsequent Events Subsequent to June 30, 2024, November 2027 .

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	ITEM 5. Other Information None
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited interim consolidated financial statements of GB Sciences, Inc. have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 8 X. not not may March 31, 2025. June 30, 2024 not 10 March 31, 2024.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation. All subsidiaries were wholly owned by the Company for the periods presented.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, collectability of notes receivable, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation and other loss contingencies. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The Company adopted ASC 820, 820 820 three three - Level 1 - Level 2 - Level 3 The carrying value of cash, accounts receivable, accounts payable and accrued expenses are estimated by management to approximate fair value, primarily due to the short-term nature of the instruments.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three no June 30, 2024 2023.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Indefinite and Definite-Lived Intangible Assets Capitalized costs related to our indefinite-lived intangible assets consisted primarily of the value of our patents pending and includes the costs paid to draft and file patent applications. Upon issuance of the patents, the indefinite-lived intangible assets will have finite lives. Intangible assets also historically included the acquisition cost of a cannabis production license with an indefinite life. We historically amortized our finite-lived intangible assets, which consisted of granted patents, over their estimated useful lives using the straight-line method, and we periodically evaluate the remaining useful lives of our finite-lived intangible assets to determine whether events or circumstances warrant a revision to the remaining period of amortization. We review all of our intangible assets for impairment indicators throughout the year. Impairment testing for indefinite-lived intangible assets is performed at least annually and we perform testing for definite-lived intangible assets whenever impairment indicators are present. If we determine that the fair value is less than the carrying value of these assets during testing, we record impairment losses equal to the difference between the carrying value of the asset and the fair market value of the asset. As of March 31, 2024, March 31, 2023 350 30 35. At June 30, 2024, eight twelve two fifteen forty-one January 2038 May 2039. June 30, 2024 2023, June 30, 2024 2023. There were 10 United States patent applications that are pending as of June 30, 2023, June 30, 2023. June 30, 2024 2023.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company’s only material revenue source is part of discontinued operations and derives from sales of cannabis and cannabis products, distinct physical goods. Under ASC 606, may may one 606 not
Share-Based Payment Arrangement [Policy Text Block]	Equity-Based Compensation The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 718 no may may may
Income Tax, Policy [Policy Text Block]	Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company operated in the State-licensed cannabis industry until the December 31, 2021 280E “280E” 280E, no not may not 280E.
Earnings Per Share, Policy [Policy Text Block]	Loss per Share The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the year. The Company had 167,396,125 and 162,611,301 potentially dilutive common shares including convertible debt, stock options and warrants at June 30, 2024 2023, not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Standards Not All other newly issued accounting pronouncements have been deemed either immaterial or not

Note 3 - Notes and Convertibl_2

Note 3 - Notes and Convertible Notes Payable and Line of Credit (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Debt [Table Text Block]	As of June 30, 2024 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (as amended) $ 55,307 $ - $ 55,307 6% Convertible promissory notes payable 560,000 - 560,000 6% Convertible notes payable due January 18, 2022 325,000 - 325,000 6% Convertible note payable due July 1, 2022 (Note 6) 50,000 - 50,000 6% Convertible promissory notes payable due September 30, 2023 197,000 - 197,000 6% Convertible note payable due December 31, 2023 250,000 - 250,000 Total short-term notes and convertible notes payable $ 1,437,307 $ 1,437,307 6% Convertible note payable due June 29, 2026 25,000 - 25,000 6% Convertible note payable due July 10, 2026 50,000 - 50,000 6% Convertible notes payable due January-February 2027 247,000 - 247,000 Total notes and convertible notes payable $ 1,759,307 $ - $ 1,759,307 As of March 31, 2024 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (as amended) $ 55,307 $ - $ 55,307 6% Convertible promissory notes payable 560,000 - 560,000 6% Convertible notes payable due January 18, 2022 325,000 - 325,000 6% Convertible note payable due July 1, 2022 (Note 6) 50,000 - 50,000 6% Convertible promissory notes payable due September 30, 2023 197,000 - 197,000 6% Convertible note payable due December 31, 2023 250,000 - 250,000 Total short-term notes and convertible notes payable $ 1,437,307 $ 1,437,307 6% Convertible note payable due June 29, 2026 25,000 - 25,000 6% Convertible note payable due July 10, 2026 50,000 - 50,000 6% Convertible notes payable due January-February 2027 247,000 - 247,000 Total notes and convertible notes payable $ 1,759,307 $ - $ 1,759,307

Note 4 - Capital Transactions (

Note 4 - Capital Transactions (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrants Outstanding Number of Shares Exercise Price Warrants issued (including reinstated) 23,006,492 $0.01 Warrants exercised (25,348,467 ) $0.01 Warrants expired/cancelled (38,337,538 ) $0.01 - $0.60 Outstanding at March 31, 2024 82,079,164 Warrants issued - $0.00 Warrants exercised (1,000,000 ) $0.01 Warrants expired/cancelled (6,293,335 ) $0.10 - $0.25 Outstanding at June 30, 2024 74,785,829
Schedule of Stock Options Roll Forward [Table Text Block]	Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Employee options Options Price $ Life (years) Value ($) Exercisable at March 31, 2023 17,733,334 $ 0.11 Granted 15,000,000 $ 0.01 Exercised - $ - Expired (2,700,000 ) $ 0.11 Forfeited (1,150,000 ) $ 0.05 Outstanding at March 31, 2024 28,883,334 $ 0.06 $ 7.06 $ - Fully vested and expected to vest at March 31, 2024 28,883,334 $ 0.06 Exercisable at March 31, 2024 28,883,334 $ 0.06 Granted - $ - Exercised - $ - Expired - $ - Forfeited - $ - Outstanding at June 30, 2024 28,883,334 $ 0.06 $ 7.06 $ - Fully vested and expected to vest at June 30, 2024 28,883,334 $ 0.06 Exercisable at June 30, 2024 28,883,334 $ 0.06 Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Nonemployee options Options Price $ Life (years) Value ($) Exercisable at March 31, 2023 6,483,000 $ 0.13 Granted 8,000,000 $ 0.01 Exercised - Forfeited - Outstanding at March 31, 2024 14,483,000 $ 0.06 7.58 -Fully vested and expected to vest at March 31, 2024 14,483,000 $ 0.06 Exercisable at March 31, 2024 14,483,000 $ 0.06 Granted - Exercised - Forfeited - Outstanding at June 30, 2024 14,483,000 $ 0.06 7.58 -Fully vested and expected to vest at June 30, 2024 14,483,000 $ 0.06 Exercisable at June 30, 2024 14,483,000 $ 0.06

Note 1 - Background and Signi_2

Note 1 - Background and Significant Accounting Policies (Details Textual)		3 Months Ended
	Sep. 26, 2024 USD ($)	Jun. 30, 2024 USD ($) shares	Jun. 30, 2023 USD ($) shares	Mar. 31, 2024 USD ($) shares	Mar. 09, 2023 shares	Mar. 08, 2023 shares	Aug. 15, 2019 shares	Aug. 14, 2019 shares	Apr. 08, 2018 shares	Mar. 31, 2018 shares
Common Stock, Shares Authorized (in shares) | shares		950,000,000		950,000,000	950,000,000	600,000,000	600,000,000	400,000,000	400,000,000	250,000,000
Deferred Tax Liabilities, Deferred Expense, Capitalized Patent Costs				$ 42,194
Amortization of Intangible Assets		$ 0	$ 624
Indefinite-Lived Intangible Assets (Excluding Goodwill)		$ 0	$ 0
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares		167,396,125	162,611,301
EndoPure [Member] | Forecast [Member]
Royalty Rates	5%
Prepaid Annual Royalty	$ 50,000
Royalty Agreement, Initial Payment	125,000
Monthly Consulting Fee	$ 5,000
Patents [Member] | UNITED STATES
Finite-Lived Intangible Assets, Number		8
Patents [Member] | UNITED STATES | Subsidiaries [Member]
Finite-Lived Intangible Assets, Number		8
Patents [Member] | Non-US [Member]
Finite-Lived Intangible Assets, Number		12
Patents [Member] | Non-US [Member] | Subsidiaries [Member]
Finite-Lived Intangible Assets, Number		12
Patents Allowed [Member] | Non-US [Member]
Finite-Lived Intangible Assets, Number		2
Patents Allowed [Member] | Non-US [Member] | Subsidiaries [Member]
Finite-Lived Intangible Assets, Number		2
Patents Pending [Member]
Indefinite-Lived Intangible Assets (Excluding Goodwill)			$ 0
Patents Pending [Member] | UNITED STATES
Indefinite-Lived Intangible Assets, Pending, Number		15	10
Patents Pending [Member] | UNITED STATES | Subsidiaries [Member]
Finite-Lived Intangible Assets, Number		15
Patents Pending [Member] | Non-US [Member]
Indefinite-Lived Intangible Assets, Pending, Number		41	35
Patents Pending [Member] | Non-US [Member] | Subsidiaries [Member]
Finite-Lived Intangible Assets, Number		41

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) - USD ($)	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2024
Retained Earnings (Accumulated Deficit)	$ (110,352,010)		$ (110,066,992)
Working Capital (Deficit)	(5,267,133)	$ (4,655,504)
Net Cash Provided by (Used in) Operating Activities	$ (21,991)	$ (105,301)

Note 3 - Notes and Convertibl_3

Note 3 - Notes and Convertible Notes Payable and Line of Credit (Details Textual)						1 Months Ended			3 Months Ended			6 Months Ended	9 Months Ended		12 Months Ended
	Mar. 04, 2022 USD ($)	Jan. 20, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 14, 2021 USD ($)	Oct. 23, 2017 USD ($)	Feb. 07, 2024 USD ($) $ / shares	Jul. 31, 2017 USD ($) $ / shares	Mar. 31, 2017 USD ($) $ / shares	Jun. 30, 2024 USD ($) shares	Jun. 30, 2023 USD ($)	May 31, 2017 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2021 USD ($)	Dec. 18, 2020 USD ($) $ / shares	Mar. 31, 2024 USD ($) shares	Mar. 31, 2022 USD ($) $ / shares shares	Nov. 13, 2023 $ / shares	Nov. 12, 2023 $ / shares	Aug. 10, 2020 USD ($)
Debt Instrument, Face Amount									$ 1,759,307						$ 1,759,307
Class of Warrant or Right, Issued During Period (in shares) | shares									0						23,006,492
Proceeds from Convertible Debt									$ 0	$ 25,000
Warrants Issued in March 2017 Convertible Note Offering [Member]
Debt Instrument, Convertible, Number of Warrants								4,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 0.6			$ 0.6
Warrants and Rights Outstanding, Term (Year)								3 years			3 years
Class of Warrant or Right, Issued (in shares) | shares											8,000,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares											1
Warrants Issued In March 2017 and July 2017 Convertible Note Offerings [Member]
Debt Instrument, Convertible, Number of Warrants							4,000
Class of Warrant or Right, Issued During Period (in shares) | shares																788,000
Warrants Related to July 2017 Convertible Note Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares							$ 0.65					$ 0.6
Warrants and Rights Outstanding, Term (Year)												3 years
Class of Warrant or Right, Issued (in shares) | shares												28,804,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares												1
Warrants Issued in September 30, 2023, Convertible Note Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																$ 0.1
Warrants and Rights Outstanding, Term (Year)																3 years
Warrants and Rights Outstanding																$ 13,396
Warrants Issued with Convertible Note Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 0.01
GB Sciences Nopah, LLC [Member]
Receivable with Imputed Interest, Effective Yield (Interest Rate)													8%
Extinguishment of Debt, Amount													$ 3,462,854
GB Sciences Nopah, LLC [Member] | Accounts Payable Due to Affiliate of the Purchaser [Member]
Extinguishment of Debt, Amount			$ 74,647	$ 74,647
The 0% Note Payable Dated October 23, 2017 [Member] | Convertible Notes Payable [Member]
Debt Instrument, Face Amount									55,307						$ 55,307
March 2017 Convertible Note Offering [Member] | Convertible Notes Payable [Member]
Debt Instrument, Interest Rate, Stated Percentage								6%
Debt Instrument, Face Amount											$ 2,000,000
Debt Instrument, Term (Year)											3 years
Debt Instrument, Unamortized Discount, Total											$ 1,933,693
Debt Instrument, Face Amount Per Note								$ 1,000
Debt Instrument, Convertible, Beneficial Conversion Feature											904,690
Debt Instrument, Convertible, Discount, Fair Value of Warrants											$ 1,029,003
March 2017 Convertible Note Offering [Member] | Convertible Notes Payable [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments								4,000			8,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares								$ 0.25
July 2017 Convertible Note Offering [Member] | Convertible Notes Payable [Member]
Debt Instrument, Interest Rate, Stated Percentage							6%
Debt Instrument, Face Amount												$ 7,201,000
Debt Instrument, Term (Year)							3 years					3 years
Debt Instrument, Unamortized Discount, Total												$ 7,092,796
Debt Instrument, Face Amount Per Note							$ 1,000
Debt Instrument, Convertible, Beneficial Conversion Feature												3,142,605
Debt Instrument, Convertible, Discount, Fair Value of Warrants												$ 3,950,191
July 2017 Convertible Note Offering [Member] | Convertible Notes Payable [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments							4,000					28,804,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares							$ 0.25
March And July 2017 Convertible Note Offering [Member] | Convertible Notes Payable [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares																$ 0.1
Debt Instrument, Extended Amount																$ 197,000
Convertible Notes Payable, Total																$ 1,257,000
The 6 % Convertible Note Offering Dated December 2020 [Member]
Debt Instrument, Interest Rate, Stated Percentage														6%
Debt Instrument, Face Amount														$ 700,000
Debt Instrument, Unamortized Discount, Total									0
Interest Payable									141,263
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares														$ 0.05		$ 0.03	$ 0.01
Interest Expense, Debt									11,967	10,849
The 6 % Convertible Note Offering Dated December 2020 [Member] | Convertible Debt Converted to Common Shares, Out of The Money [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares																	$ 0.01	$ 0.03
The 6 % Convertible Note Offering Dated December 2020 [Member] | Three Investors [Member]
Debt Instrument, Face Amount														$ 625,000
The 6 % Convertible Note Payable, Maturity, January 31, 2021 to July 1, 2022 [Member] | Three Investors [Member]
Debt Instrument, Face Amount														375,000
The 6 % Convertible Note Payable Mature in December 2023 [Member] | Three Investors [Member]
Debt Instrument, Face Amount														250,000
The 6 Percent Convertible Note Payable Issued With In Money Conversion Features [Member]
Debt Instrument, Face Amount														425,000
Debt Instrument, Unamortized Discount, Total														81,250		$ 6,500
Debt Instrument, Convertible, Beneficial Conversion Feature														347,000
Proceeds from Convertible Debt														$ 543,750		50,000
The 6 Percent Note Payable Due June 30, 2026 [Member]
Proceeds from Convertible Debt															25,000
The 6% Convertible Note Payable Due July 10, 2026 [Member]
Proceeds from Convertible Debt															50,000
The 6% Convertible Note Payable Due January to February 2027 [Member]
Debt Instrument, Interest Rate, Stated Percentage						6%
Debt Instrument, Face Amount						$ 500,000
Debt Instrument, Term (Year)						3 years
Interest Payable									6,145
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares						$ 0.01
Interest Expense, Debt									3,695	0
Proceeds from Convertible Debt						$ 247,000
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Debt Instrument, Interest Rate, Stated Percentage					0%														0%
Debt Instrument, Face Amount					$ 700,000
Debt Instrument, Term (Year)					3 years
Debt Instrument, Present Value					$ 521,067
Receivable with Imputed Interest, Effective Yield (Interest Rate)					20.30%
Debt Instrument, Unamortized Discount, Total					$ 178,933
Notes Payable, Current, Total			$ 369,445										$ 369,445
Notes Payable, Principal and Interest	$ 201,532
Notes Payable, Principal and Interest, After Modified Terms	179,127
Repayment of Notes Payable	75,000								0
Debt Instrument, Monthly Payment, Amount	$ 5,000
Debt Instrument, Interest Rate, Stated Percentage, After Term Modification	8%
Notes Payable, Current and Noncurrent									55,307
Interest Payable									5,867
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | Membership Interest Purchase Agreement for Sale of Interest in GB Sciences Nopah, LLC [Member]
Debt Instrument, Principal Balance After Reduction Upon Close of Disposition																			$ 190,272
Convertible Debt [Member]
Interest Payable									251,862
Convertible Notes Payable, Total		$ 560,000
Interest Expense, Debt									11,169	11,169
Debt Instrument, Debt Default, Amount									1,060,000
Repayments of Convertible Debt		$ 500,000
Convertible Debt [Member] | March And July 2017 Convertible Note Offering [Member]
Debt Instrument, Unamortized Discount, Total									0							46,886
Interest Payable									82,772
Debt Instrument, Convertible, Beneficial Conversion Feature																$ 33,490
Debt Instrument, Extended Amount									197,000
Interest Expense, Debt									2,947	$ 2,947
Convertible Debt [Member] | The 6% Convertible Note Payable Due January to February 2027 [Member]
Debt Instrument, Face Amount									$ 247,000						$ 247,000
Nevada Medical Marijuana Production License Agreement [Member]
Payments to Acquire License					$ 500,000
Nevada Medical Marijuana Production License Agreement [Member] | Production License [Member]
Ownership of License					100%
Nevada Medical Marijuana Production License Agreement [Member] | Cultivation License [Member]
Ownership of License					100%

Note 3 - Notes and Convertibl_4

Note 3 - Notes and Convertible Notes Payable and Line of Credit - Summary of Notes and Convertible Notes Payable (Details) - USD ($)	Jun. 30, 2024	Mar. 31, 2024	Feb. 07, 2024
Face value, long-term notes payable	$ 1,759,307	$ 1,759,307
Discount, long-term notes payable	0	0
Total notes and convertible notes payable	1,759,307	1,759,307
The 6% Convertible Note Payable Due July 30, 2026 [Member] | Convertible Debt [Member]
Face value, long-term notes payable	25,000	25,000
Discount, long-term notes payable	0	0
Carrying value, long-term notes payable	25,000	25,000
The Second 6% Convertible Note Payable Due July 30, 2026 [Member] | Convertible Debt [Member]
Face value, long-term notes payable	50,000	50,000
Discount, long-term notes payable	0	0
Carrying value, long-term notes payable	50,000	50,000
The 6% Convertible Note Payable Due January to February 2027 [Member]
Face value, long-term notes payable			$ 500,000
The 6% Convertible Note Payable Due January to February 2027 [Member] | Convertible Debt [Member]
Face value, long-term notes payable	247,000	247,000
Discount, long-term notes payable	0	0
Carrying value, long-term notes payable	247,000	247,000
Convertible Notes Payable [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Face value, long-term notes payable	55,307	55,307
Discount, long-term notes payable	0	0
Carrying value, long-term notes payable	55,307	55,307
Convertible Notes Payable [Member] | The 6% Note Payable Due November 30, 2018 [Member]
Face value, long-term notes payable	560,000	560,000
Discount, short-term notes payable	0	0
Carrying value, short-term notes payable	560,000	560,000
Convertible Notes Payable [Member] | The 6% Notes Payable Due January 18, 2022 [Member]
Face value, long-term notes payable	325,000	325,000
Discount, long-term notes payable	0	0
Carrying value, short-term notes payable	325,000	325,000
Convertible Notes Payable [Member] | The6PercentNotesPayableDueJuly12022Member
Face value, long-term notes payable	50,000	50,000
Discount, long-term notes payable	0	0
Carrying value, short-term notes payable	50,000	50,000
Convertible Notes Payable [Member] | The 6 % Note Payable Dated September 30, 2023 [Member]
Face value, long-term notes payable	197,000	197,000
Discount, long-term notes payable	0	0
Carrying value, long-term notes payable	197,000	197,000
Convertible Notes Payable [Member] | The 6 % Convertible Note Payable Dated December 31, 2023 [Member]
Face value, long-term notes payable	250,000	250,000
Discount, long-term notes payable	0	0
Carrying value, long-term notes payable	250,000	250,000
Promissory Note [Member]
Face value, long-term notes payable	1,437,307	1,437,307
Carrying value, long-term notes payable	$ 1,437,307	$ 1,437,307

Note 4 - Capital Transactions_2

Note 4 - Capital Transactions (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2024
Adjustments to Additional Paid in Capital, Warrant Reinstatement and Repricing	$ (3,462)
Proceeds from Warrant Exercises	$ 10,000	$ 0
Class of Warrant or Right, Cancelled During Period (in shares)	6,293,335		38,337,538
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)	0	0
Unexpired Warrants To Investors [Member]
Class of Warrant or Right, Repriced (in shares)	1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.01		$ 0.1
Warrants Issued to Investor [Member]
Class of Warrant or Right, Repriced (in shares)			92,657,209
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.01
Adjustments to Additional Paid in Capital, Warrant Reinstatement and Repricing	$ 3,462
Class of Warrant or Right, Reinstated (in shares)			23,006,492
Deemed Dividend for Reissuance of Warrants			$ 278,315
Warrants at Exercise Price of 0.25 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.25
Class of Warrant or Right, Expired During Period (in shares)	4,198,002
Warrants at Exercise Price of 0.10 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.1
Class of Warrant or Right, Expired During Period (in shares)	2,095,333		3,490,834
Class of Warrant or Right, Expired During Period, Exercise Price (in dollars per share)			$ 0.1
Warrants [Member]
Class of Warrant or Right, Expired During Period (in shares)			2,456,750
Class of Warrant or Right, Exercises in Period (in shares)	1,000,000		25,348,467
Class of Warrant or Right, Exercises in Period, Exercise Price (in dollars per share)	$ 0.01		$ 0.01
Proceeds from Warrant Exercises	$ 10,000		$ 253,529
Class of Warrant or Right, Expired During Period, Exercise Price (in dollars per share)			$ 0.1
Brokerage Fees, Exercise of Warrants			$ 17,752
Class of Warrant or Right, Cancelled During Period (in shares)			1,150,000
Payments for Repurchase of Warrants			$ 0
Warrant at Exercise Price of 0.06 [Member]
Class of Warrant or Right, Expired During Period (in shares)			4,295,500
Class of Warrant or Right, Expired During Period, Exercise Price (in dollars per share)			$ 0.6
Warrant at Exercise Price of 0.04 [Member]
Class of Warrant or Right, Expired During Period (in shares)			300,000
Class of Warrant or Right, Expired During Period, Exercise Price (in dollars per share)			$ 0.04

Note 4 - Capital Transactions -

Note 4 - Capital Transactions - Warrant Activity (Details) - $ / shares	3 Months Ended	12 Months Ended
	Jun. 30, 2024	Mar. 31, 2024
Warrants issued (including reinstated) (in shares)	0	23,006,492
Warrants issued, exercise price (in dollars per share)	$ 0	$ 0.01
Warrants exercised (in shares)	(1,000,000)	(25,348,467)
Warrants exercised, exercise price (in dollars per share)	$ 0.01	$ 0.01
Warrants expired/cancelled (in shares)	(6,293,335)	(38,337,538)
Outstanding (in shares)	74,785,829	82,079,164
Maximum [Member]
Warrants expired/cancelled, exercise price (in dollars per share)	$ 0.25	$ 0.6
Minimum [Member]
Warrants expired/cancelled, exercise price (in dollars per share)	$ 0.1

Note 4 - Capital Transactions_3

Note 4 - Capital Transactions - Option Activity (Details) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Mar. 31, 2023
Exercisable, options (in shares)	28,883,334
Exercisable, weighted average exercise price (in dollars per share)	$ 0.06
Expired, options (in shares)	0	(2,700,000)
Expired, weighted average exercise price (in dollars per share)	$ 0	$ 0.11
Fully vested and expected to vest, options (in shares)	28,883,334
Fully vested and expected to vest, weighted average exercise price (in dollars per share)	$ 0.06
Share-Based Payment Arrangement, Employee [Member]
Exercisable, options (in shares)		28,883,334	17,733,334
Exercisable, weighted average exercise price (in dollars per share)		$ 0.06	$ 0.11
Granted, options (in shares)	0	15,000,000
Granted, weighted average exercise price (in dollars per share)	$ 0	$ 0.01
Exercised, options (in shares)	0	0
Exercised, weighted average exercise price (in dollars per share)	$ 0	$ 0
Forfeited, options (in shares)	0	(1,150,000)
Forfeited, weighted average exercise price (in dollars per share)	$ 0	$ 0.05
Outstanding, weighted average remaining contractual life (Year)	7 years 21 days	7 years 21 days
Outstanding, aggregate intrinsic value	$ 0	$ 0
Fully vested and expected to vest, options (in shares)		28,883,334
Fully vested and expected to vest, weighted average exercise price (in dollars per share)		$ 0.06
Forfeited, options (in shares)	0	1,150,000
Outstanding, options (in shares)	28,883,334	28,883,334
Outstanding, weighted average exercise price (in dollars per share)	$ 0.06	$ 0.06
Outstanding, options (in shares)	28,883,334
Outstanding, weighted average exercise price (in dollars per share)	$ 0.06
Share-Based Payment Arrangement, Nonemployee [Member]
Exercisable, options (in shares)	14,483,000	14,483,000	6,483,000
Exercisable, weighted average exercise price (in dollars per share)	$ 0.06	$ 0.06	$ 0.13
Granted, options (in shares)	0	8,000,000
Granted, weighted average exercise price (in dollars per share)		$ 0.01
Exercised, options (in shares)	0	0
Forfeited, options (in shares)	0	0
Outstanding, weighted average remaining contractual life (Year)	7 years 6 months 29 days	7 years 6 months 29 days
Outstanding, aggregate intrinsic value
Fully vested and expected to vest, options (in shares)	14,483,000	14,483,000
Fully vested and expected to vest, weighted average exercise price (in dollars per share)	$ 0.06	$ 0.06
Forfeited, options (in shares)	0	0
Outstanding, options (in shares)	14,483,000
Outstanding, weighted average exercise price (in dollars per share)	$ 0.06
Outstanding, options (in shares)		14,483,000
Outstanding, weighted average exercise price (in dollars per share)		$ 0.06

Note 5 - Commitments and Cont_2

Note 5 - Commitments and Contingencies (Details Textual)	Jun. 30, 2024 USD ($)
Purchase Commitment [Member]
Contractual Obligation	$ 235,000

Note 6 - Related Party Transa_2

Note 6 - Related Party Transactions (Details Textual) - USD ($)	3 Months Ended
	Jun. 30, 2024	Mar. 31, 2024
Chief Executive Officer [Member]
Accounts Payable, Current	$ 108,816
Costs and Expenses, Related Party	7,634
President and Director [Member]
Accounts Payable, Current	18,498
Related Party [Member]
Accounts Payable, Current	$ 134,949	$ 127,436

Note 7 - Note Receivable from_2

Note 7 - Note Receivable from Sale of Membership Interests in Nevada Subsidiaries (Details Textual)								9 Months Ended	12 Months Ended
	Mar. 27, 2023 USD ($)	Dec. 31, 2021 USD ($)	Dec. 14, 2021 USD ($)	Aug. 10, 2020 USD ($)	Mar. 24, 2020 USD ($)	Nov. 27, 2019	Oct. 23, 2017	Dec. 31, 2021 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2022 USD ($)
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Debt Instrument, Interest Rate, Stated Percentage				0%			0%
Receivable with Imputed Interest, Effective Yield (Interest Rate)							20.30%
GB Sciences Nopah, LLC [Member]
Sale of Stock, Percentage of Ownership						100%
Noncash or Part Noncash Divestiture, Amount of Consideration Received				$ 312,315
Nevada Subsidiaries [Member]
Sale of Stock, Percentage of Ownership					100%
Teco Subsidiaries [Member]
Sale of Stock, Consideration Received on Transaction					$ 8,000,000
Notes Receivable, Interest Rate					8%
GB Sciences Nopah, LLC [Member]
Notes Reduction	$ 504,167			$ 237,668
Extinguishment of Debt, Amount								$ 3,462,854
Sale of Stock, Percentage of Ownership before Transaction		100%
Sale of Stock, Percentage of Ownership after Transaction		0%
Proceeds from Divestiture of Interest in Consolidated Subsidiaries								1,648,772
Proceeds From Divestiture of Business, Advances Received		$ 400,000						400,000
Financing Receivable, after Allowance for Credit Loss, Total		3,025,000						$ 3,025,000	$ 60,500	$ 60,500
Receivable with Imputed Interest, Effective Yield (Interest Rate)								8%
Quarterly Interest Only Payments on Note Receivable, Years									1	1
Number of Quarterly Principal and Interest Payments on Note Receivable									7	7
Note Receivable, Quarterly Principal and Interest Installment									$ 201,774
Final Payment, Principal and Interest Payments Due on Note Receivable									2,014,225	$ 2,014,225
Note Receivable, Interest Only, Monthly										$ 60,500
Asset Impairment Charges, Total									$ 3,025,000
Notes Receivable, Initial Payment	100,000
Note Receivable, Additional Payment Amount	1
Note Receivable, Reduction of Principal Amount	5.0416
Notes Receivable, Additional Aggregate Amount Payments	$ 500,000
GB Sciences Nopah, LLC [Member] | Accounts Payable Due to Affiliate of the Purchaser [Member]
Extinguishment of Debt, Amount		$ 74,647	$ 74,647

Note 8 - Subsequent Events (Det

Note 8 - Subsequent Events (Details Textual) - USD ($)		3 Months Ended
	Oct. 01, 2024	Jun. 30, 2024	Jun. 30, 2023
Proceeds from Convertible Debt		$ 0	$ 25,000
Forecast [Member] | Convertible Notes Payable [Member]
Proceeds from Convertible Debt	$ 25,000
Debt Instrument, Interest Rate, Stated Percentage	6%
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 0.01